New findings on tumor reduction and survival outcomes in advanced renal cell carcinoma
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Hosted on MSN1mon
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
The researchers found that median progression-free survival was 14.6 and 10.0 months for TACE with lenvatinib plus pembrolizumab and TACE plus placebo, respectively (hazard ratio, 0.66 ...